Aldosterone status associated with insulin resistance in patients with heart failure - Data from the ALOFT study

Heart

Volumn 95, Issue 23, 2009, Pages 1920-1924

  Freel, E Marie ^a   Tsorlalis, I K ^a   Lewsey, J D ^b   Latini, R ^c   Maggioni, A P ^d   Solomon, S ^e   Pitt, B ^f   Connell, J M C ^a   McMurray, J J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Negri Institute   (Italy)

^d ANMCO RESEARCH CENTER   (Italy)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; GLUCOSE; INSULIN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; URINARY EXCRETION;

AGED; ALDOSTERONE; DIABETES MELLITUS; FASTING; FEMALE; HEART FAILURE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; RENIN;

EID: 72049094255     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.173344     Document Type: Article

References (36)

1. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro Hypertension 2007;50:447-53.
2. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8.
3. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
4. Enomoto S, Yoshiyama M, Omura T, et al. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. Heart 2005;91:1595-600.
5. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Failure 2004;6:539-45.
6. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3:486-92.
7. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150:776-83.
8. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(suppl 1):S5-20.
9. Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457-63.
10. Giacchetti G, Ronconi V, Turchi F, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007;25:177-86.
11. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
12. MacDonald MR, Petrie MC, Hawkins NM, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008;29:1224-40.
13. McMurray J, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor Aliskiren in patients with symptomatic heart failure. Circulation Heart Failure 2008;1:17-24.
14. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
15. MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
16. Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 2008;51:339-44.
17. Guder G, Bauersachs J, Frantz S, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007;115:1754-61.
18. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985;75:809-17.
19. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J of Med 1987;317:350-7.
20. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
21. Duncan ER, Crossey PA, Walker S, et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes 2008;57:3307-14.
22. Colussi G, Catena C, Lapenna R, et al. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007;30:2349-54.
23. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006;91:454-9.
24. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol 1974;34:29-34.
25. Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005;294:334-41.
26. Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008;168:1699-704.
27. Perkins JM, Davis SN. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obesity 2008;15:147-52.
28. DREAM Trial investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62.
29. Richey JM, Ader M, Moore D, et al. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol 1999;277:e920-6.
30. Mosso LM, Carvajal CA, Maiz A, et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 2007;25:2125-30.
31. Shimamoto K, Shiiki M, Ise T, et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 1994;8:755-9.
32. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000;49:1751-60.
33. Guerrero-Romero F, Rascon-Pacheco RA, Rodriguez-Moran M, et al. Hypomagnesaemia and risk for metabolic glucose disorders: a 10-year follow-up study. Eur J Clin Invest 2008;38:389-96.
34. Caprio M, Feve B, Claes A. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007;21:2185-94.
35. Ehrhart-Bornstein M, Arakelyan K, Krug AW, et al. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 2004;30:865-70.
36. Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 2003;5:106-9.